US Supreme Court temporarily lifts ban on abortion pill mail delivery

The US Supreme Court has temporarily lifted a ban on mail delivery of the abortion pill mifepristone, restoring telehealth access for at least one week. Justice Samuel Alito issued an administrative stay, pausing a lower court's decision that would have required an in-person visit to obtain the medication. This action allows the Supreme Court more time to consider emergency requests from mifepristone manufacturers while legal challenges to the drug's accessibility continue. The case stems from a challenge by Louisiana and other Republican-led states. The court's decision comes as the contentious issue of abortion access is again before the justices, with a deadline for responses set for Thursday and the administrative stay expiring May 11.

The US Supreme Court has temporarily restored broad access to the abortion pill mifepristone, blocking a lower court ruling that had imposed new restrictions. Justice Samuel Alito issued an order allowing women to obtain the pill via pharmacies or mail, reinstating rules that had been in place for years. This decision comes after a federal appeals court had limited access, following a lawsuit by Louisiana seeking to restrict the drug's availability and undermine its state ban. Mifepristone, often used with another drug, is a primary method for abortions in the US and its accessibility has been a key factor in navigating state-level abortion bans. The Supreme Court's order will remain in effect for a week while it further considers the issue.

The Supreme Court has temporarily restored broad access to the abortion pill mifepristone, blocking a lower court ruling that had sought to impose new restrictions. Justice Samuel Alito signed the order, allowing women to obtain the pill via pharmacies or mail without an in-person doctor's visit, reinstating rules that had been in place for years. This decision comes after a federal appeals court had previously limited access to the medication. Mifepristone, often used in combination with another drug, is a primary method for medication abortions in the United States. The lawsuit originated from Louisiana, which argued that the pill's availability conflicted with its state-level abortion ban.

A US appeals court has limited mail-order access to the abortion pill mifepristone, overriding a lower court's pause on the case. The Supreme Court had previously rejected an effort to restrict the drug's access in 2024, but this new ruling allows for further review of FDA regulations. Proponents of the decision, like Louisiana's Attorney General, argue it protects unborn fetuses, while opponents, such as the ACLU and New York's Attorney General, contend it restricts vital healthcare, particularly for those in rural areas or with disabilities. Mifepristone, approved in 2000 and later expanded for use up to 10 weeks of pregnancy, works by blocking progesterone. It is also used for miscarriage management and Cushing syndrome.